ALLARITY THERAPEUTICS INC (ALLR)

US0167444019 - Common Stock

1.48  -0.06 (-3.9%)

Fundamental Rating

0

Taking everything into account, ALLR scores 0 out of 10 in our fundamental rating. ALLR was compared to 588 industry peers in the Biotechnology industry. ALLR has a bad profitability rating. Also its financial health evaluation is rather negative. ALLR does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALLR had negative earnings in the past year.
ALLR had a negative operating cash flow in the past year.
In the past 5 years ALLR always reported negative net income.
In the past 5 years ALLR always reported negative operating cash flow.

1.2 Ratios

ALLR has a Return On Assets of -172.16%. This is amonst the worse of the industry: ALLR underperforms 88.38% of its industry peers.
Industry RankSector Rank
ROA -172.16%
ROE N/A
ROIC N/A
ROA(3y)-123.53%
ROA(5y)-87.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALLR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

ALLR has more shares outstanding than it did 1 year ago.
The debt/assets ratio for ALLR has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -16.76, we must say that ALLR is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -16.76, ALLR is doing worse than 84.10% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -16.76
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

ALLR has a Current Ratio of 0.14. This is a bad value and indicates that ALLR is not financially healthy enough and could expect problems in meeting its short term obligations.
ALLR has a Current ratio of 0.14. This is amonst the worse of the industry: ALLR underperforms 99.32% of its industry peers.
A Quick Ratio of 0.14 indicates that ALLR may have some problems paying its short term obligations.
The Quick ratio of ALLR (0.14) is worse than 99.15% of its industry peers.
Industry RankSector Rank
Current Ratio 0.14
Quick Ratio 0.14

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 90.64% over the past year.
EPS 1Y (TTM)90.64%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q99.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, ALLR will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.86% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.29%
EPS Next 2Y41.16%
EPS Next 3Y25.85%
EPS Next 5Y18.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALLR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALLR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

ALLR's earnings are expected to grow with 25.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.16%
EPS Next 3Y25.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALLR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALLARITY THERAPEUTICS INC

NASDAQ:ALLR (4/19/2024, 2:58:57 PM)

1.48

-0.06 (-3.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.15M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -172.16%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.14
Quick Ratio 0.14
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)90.64%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y99.29%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y